ArticleBMC public health2026

Real-world cost evaluation of conbercept vs. ranibizumab for retinal and choroidal vascular diseases from 2021 to 2024: evidence from societal and medical insurance perspectives.

Yuanyuan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.